Literature DB >> 12408468

Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults.

K Jung1, M Lein, K v Hösslin, A Grosse, S Roth, K Possinger, D Lüftner.   

Abstract

AIMS: Osteoprotegerin and the receptor activator of the nuclear factor-kappaB ligand (RANKL) are decisive factors for maintaining the balance between bone formation and bone resorption. As new, sensitive ELISAs have been developed recently, reference serum ranges should be established to use these analytes for possible diagnostic purposes.
METHODS: Measurements were performed in serum samples of 142 healthy adults (82 women, 60 men) between 20 and 70 years of age (mean age: 46 years) using ELISA kits from Immundiagnostik, Bensheim, Germany.
RESULTS: Serum concentrations of osteoprotegerin were age and gender independent and showed a Gaussian distribution, while RANKL concentrations were also age independent but differed between males and females, with a non-Gaussian distribution. For osteoprotegerin a gender-independent upper 97.5 percentile limit of 3.6 pmol/L was calculated while the corresponding limits for RANKL and the ratio of RANKL to osteoprotegerin amounted to 3.29 pmol/L and 2.78 in women and 1.66 pmol/L and 2.18 in men, respectively.
CONCLUSIONS: Both osteoprotegerin and RANKL were quantifiable in serum of healthy adults, which means that these compounds can be used as potential diagnostic tools.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408468     DOI: 10.1177/172460080201700306

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  4 in total

1.  Enhanced mineralization potential of vascular cells from SM22α-Rankl (tg) mice.

Authors:  S Morony; A P Sage; T Corbin; J Lu; Y Tintut; L L Demer
Journal:  Calcif Tissue Int       Date:  2012-10-09       Impact factor: 4.333

2.  Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

Authors:  Olafur S Indridason; Leifur Franzson; Gunnar Sigurdsson
Journal:  Osteoporos Int       Date:  2004-07-20       Impact factor: 4.507

Review 3.  Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders.

Authors:  Natalia Carrillo-López; Laura Martínez-Arias; Jorge B Cannata-Andía; Manuel Naves-Díaz; Sara Panizo; Sara Fernández-Villabrille; María Piedad Ruiz-Torres; Adriana Dusso
Journal:  Calcif Tissue Int       Date:  2021-02-13       Impact factor: 4.333

4.  Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.

Authors:  Osama E Amer; Kaiser Wani; Mohammed G A Ansari; Abdullah M Alnaami; Naji Aljohani; Saba Abdi; Syed D Hussain; Nasser M Al-Daghri; Majed S Alokail
Journal:  Medicina (Kaunas)       Date:  2022-07-22       Impact factor: 2.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.